ALCLS Stock Overview
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells.
Cellectis S.A. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€2.74|
|52 Week High||€3.90|
|52 Week Low||€0.89|
|1 Month Change||198.20%|
|3 Month Change||40.45%|
|1 Year Change||24.48%|
|3 Year Change||-87.36%|
|5 Year Change||-85.17%|
|Change since IPO||-81.46%|
Recent News & Updates
A Look At The Intrinsic Value Of Cellectis S.A. (EPA:ALCLS)Feb 07
Analyst Forecasts Just Became More Bearish On Cellectis S.A. (EPA:ALCLS)Aug 09
Is Cellectis (EPA:ALCLS) Using Too Much Debt?Dec 14
Analysts' Revenue Estimates For Cellectis S.A. (EPA:ALCLS) Are Surging HigherAug 07
We Think Some Shareholders May Hesitate To Increase Cellectis S.A.'s (EPA:ALCLS) CEO CompensationMay 26
Is Cellectis (EPA:ALCLS) Using Debt Sensibly?May 17
These Analysts Think Cellectis S.A.'s (EPA:ALCLS) Sales Are Under ThreatMar 08
Cellectis (EPA:ALCLS) Is In A Strong Position To Grow Its BusinessFeb 16
Are Institutions Heavily Invested In Cellectis S.A.'s (EPA:ALCLS) Shares?Jan 12
Analysts Are Betting On Cellectis S.A. (EPA:ALCLS) With A Big Upgrade This WeekDec 08
|ALCLS||FR Biotechs||FR Market|
Return vs Industry: ALCLS exceeded the French Biotechs industry which returned -5.4% over the past year.
Return vs Market: ALCLS exceeded the French Market which returned 6.5% over the past year.
|ALCLS Average Weekly Movement||53.7%|
|Biotechs Industry Average Movement||7.4%|
|Market Average Movement||4.4%|
|10% most volatile stocks in FR Market||9.9%|
|10% least volatile stocks in FR Market||2.1%|
Stable Share Price: ALCLS is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 54% a week.
Volatility Over Time: ALCLS's weekly volatility has increased from 28% to 54% over the past year.
About the Company
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL.
Cellectis S.A. Fundamentals Summary
|ALCLS fundamental statistics|
Is ALCLS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALCLS income statement (TTM)|
|Cost of Revenue||US$1.26m|
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
|Earnings per share (EPS)||-1.00|
|Net Profit Margin||-293.13%|
How did ALCLS perform over the long term?See historical performance and comparison